Filing Flows › Gyre Therapeutics (GYRE) › R&D spending
Gyre Therapeutics (GYRE) R&D spending by quarter
Gyre Therapeutics' R&D spending was $6.7M in Q1 2026 (first quarter 2026), +40% from Q4 2025. Over the last 5 quarters it ranged from $2.4M (Q3 2025) to $6.7M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $6.7M | +40% | +118% |
| Q4 2025 | $4.8M | +104% | — |
| Q3 2025 | $2.4M | -31% | — |
| Q2 2025 | $3.4M | +11% | — |
| Q1 2025 | $3.1M | — | — |
Q1 2026 at a glance
Gyre Therapeutics, Q1 2026: revenue $22.5M (+2% year over year), operating margin -41.5%, net loss $9.9M, operating cash flow $3.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Gyre Therapeutics' R&D spending?
Gyre Therapeutics' R&D spending was $6.7M in Q1 2026 (first quarter 2026), +40% from Q4 2025.
How has Gyre Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $2.4M (Q3 2025) to $6.7M (Q1 2026).